PhRMA
@PhRMAWe represent America's innovative biopharmaceutical research & biotechnology companies. Subscribe to alerts at https://t.co/H3Y6VehuC4. @SteveUbl CEO
Similar User
@FiercePharma
@pharminews
@PharmaTimes
@EliLillyandCo
@pharmalive
@JNJNews
@ThePharmaLetter
@PharmTechGroup
@Pharmafocus
@FierceBiotech
@ContractPharma
@pharmaphorum
@IAmBiotech
@FiercePharmaMkt
@pfizer
Congress should make sure savings on medicines go to patients, not PBMs. phrma.org/Blog/PhRMA-lau…
New research from @Health_Affairs examines how the IRA impacts post-approval R&D that has been pivotal in the fight against cancer. We know what’s wrong with the law. Now lawmakers need to fix it. phrma.org/Blog/Post-appr…
We continue to have serious concerns about persistent and often illegal abuse of 340B, which is driving up costs for patients, employers and taxpayers. Read our statement here: phrma.org/resource-cente…
The current administration’s proposed march-in framework threatens the future of oncology R&D, @EliLillyandCo CEO Dave Ricks explains.
This #NationalFamilyCaregiversMonth is a moment to recognize the substantial toll that Alzheimer’s disease has on the loved ones of patients living with this devastating condition. Watch more from @EliLillyandCo's Anne White & PhRMA's @lreilly71: phrma.org/Blog/Alzheimer…. #ENDALZ
A new @WHO report puts a spotlight on yet another downstream benefit of vaccines – their ability to lower antibiotic use, decrease resources spent treating resistant infections and reduce the global burden of antimicrobial resistance. Learn more: phrma.org/Blog/Leveragin… #AMR
Our Chief Medical Officer @mybarra recently participated in the @CDCgov's Advisory Committee on Immunization Practices. See the key takeaways here about what was discussed: phrma.org/Blog/Key-Takea…
Addressing policymakers, @mybarra weighs in on the importance of creating policies that both alleviate patient concerns and improve access to lifesaving medicines.
According to the latest Patient Experience Survey, out-of-pocket costs lead key health care priorities ahead of the November election. Read more: phrma.org/Blog/New-PES-s…
“I want my doctor to decide my medications, not someone behind a desk at an office who has never met me,” says Renne, a @votersforcures advocate in Arizona. On November 5, candidates need to put patients first. No one should have to fight a middleman for their right to breathe.…
The latest Patient Experience Survey finds that many insured Americans’ experience with the health care system continues to be influenced by access and affordability challenges, and specifically, insurer- and PBM-imposed hurdles. Learn more: phrma.org/Blog/Patient-E…
Today, new medicines allow for better, more targeted treatments of breast cancer. We need to preserve the system that enables this R&D by removing the obstacles that are keeping science from moving forward. More from @EA_Carpenter in @pharmaboardroom: pharmaboardroom.com/articles/extra…
Biopharmaceutical innovation is ushering in the next generation of advanced medicines. Here, Thomas Miller of @BayerPharma shares his personal connection to the research pipeline and what’s on the horizon for medicines that impact young children and infants.
Last week, we submitted a letter to HRSA asking them to allow manufacturers to use alternative approaches to provide #340B prices to enhance program integrity. It’s clear 340B isn’t working for patients as it should, and program violations have long gone unaddressed.…
When it comes to health care, voters are calling for meaningful solutions – starting with holding big insurers and their PBM middlemen accountable. Read our new blog for the latest insights into voters’ priorities: phrma.org/Blog/Where-vot…
Alzheimer’s is a devastating disease that can rob a person of everything they hold dear, including their memories. But the evolving treatment paradigm for Alzheimer's disease could change the lives of patients and their caregivers, says Ying Tang of @EliLillyandCo
“Unfortunately, many of our elected leaders today undervalue the role of patents to progress the science of drug discovery and look for policies to weaken them,” writes Eli Lilly’s Daniel… trib.al/tkAhAvX
Our CEO @steveubl addresses the impact of the Inflation Reduction Act, highlighting how it creates barriers between patients and their medicines.
Medicare’s new “cap & smoothing” policies will make a real difference for patients. It’s crucial patients know about these changes in Part D and understand their options. US Commercial Head Mike Petroutsas discusses the positive benefits for seniors here: bit.ly/3U7Xj19
United States Trends
- 1. Brian Kelly 5.918 posts
- 2. Gators 9.346 posts
- 3. Louisville 4.938 posts
- 4. Feds 33,1 B posts
- 5. Nuss 3.029 posts
- 6. #UFC309 35,6 B posts
- 7. Stanford 8.173 posts
- 8. Billy Napier 1.528 posts
- 9. Nebraska 8.982 posts
- 10. Mizzou 3.918 posts
- 11. Lagway 3.995 posts
- 12. Brohm N/A
- 13. #Huskers 1.346 posts
- 14. Tyler Warren 1.948 posts
- 15. Raiola N/A
- 16. Ron English N/A
- 17. #MostRequestedLive 4.582 posts
- 18. Baylor 3.282 posts
- 19. Heisman 13,2 B posts
- 20. Moura 6.773 posts
Who to follow
-
FiercePharma
@FiercePharma -
Pharma & Life Science News
@pharminews -
PharmaTimes
@PharmaTimes -
Eli Lilly and Company
@EliLillyandCo -
PharmaLive
@pharmalive -
Johnson & Johnson
@JNJNews -
The Pharma Letter
@ThePharmaLetter -
PharmTech Group
@PharmTechGroup -
Pharmafocus
@Pharmafocus -
FierceBiotech
@FierceBiotech -
Contract Pharma
@ContractPharma -
pharmaphorum
@pharmaphorum -
I Am Biotech
@IAmBiotech -
Fierce Pharma Marketing
@FiercePharmaMkt -
Pfizer Inc.
@pfizer
Something went wrong.
Something went wrong.